Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 6, 2011, Pages 555-560

  Luo, Hui Yan ^a   Wang, Zhi Qiang ^a   Wang, Feng Hua ^a   Qiu, Miao Zhen ^a   Teng, Kai Yuan ^a   Ruan, Dan Yun ^a   He, You Jian ^a   Li, Yu Hong ^a   Xu, Rui Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

capecitabine; gastric cancer; irinotecan; phase 2 trial

Indexed keywords

CAPECITABINE; IRINOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHOLINERGIC SYNDROME; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 81855166688     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181f47ac1     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin 2005;55:74-108. Doi: 10.3322/canjclin. 55.2.74.
2. Yang L, Parkin DM, Whelan S, et al. Statistics on cancer in China: cancer registration in 2002. Eur J Cancer Prev. 2005;14:329-335. Doi:10.1158/1055- 9965.
3. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multiinstitutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23: 5660-5667. Doi: 10.1200/JCO.2005.17.376
4. Barone C, Corsi DC, Pozzo C, et al. Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies. Cancer. 1998;82:1460-1467.
5. Moehler M, Eimermacher A, Siebler J, et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) versus 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer. 2005;92:2122-2128. Doi: 10.1038/sj.bjc.6602649.
6. Nardi M, Azzarello D, Maisano R, et al. FOLFOX-4 regimen as first-line chemotherapy in elderly patients with advanced gastric cancer: a safety study. J Chemother. 2007;19:85-89.
7. Ohtsu A, Yoshida S, Saijo N, et al. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188-2196. Doi: 10.1200/JCO.2006.05.9758.
8. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24: 4991-4997. Doi: 10.1200/JCO.2006.06. 8429.
9. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19:1450-1457. Doi:10.1093/annonc/mdn166.
10. Louvet C, Andre T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol. 2002;20:4543-4548.
11. Chun JH, Kim HK, Lee JS, et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol. 2004;34:8-13.
12. Futatsuki K, Wakui A, Nakao I, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-C11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho. 1994;21:1033-1038.
13. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and metaanalysis based on aggregate data. J Clin Oncol. 2006;24:2903-2909. Doi: 10.1200/JCO.2005.05.0245
14. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282-2292.
15. Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol. 1998;16:1795-1802.
16. Mackean MJ, Planting AS, Twelves C, et al. Phase I and pharmacological study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol. 1998;16:2977-2985.
17. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5- fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666-673. Doi:10.1093/annonc/mdn717.
18. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36-46.
19. Azrak RG, Cao S, Slocum HK, et al. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res. 2004;10:1121-1129. Doi: 10.1158/1078-0432.CCR- 0913-3.
20. Mullany S, Svingen PA, Kaufmann SH, et al. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN- 38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol. 1998;42:391-399. Doi: 10.1007/s002800050835.
21. Rea DW, Nortier JW, Ten Bokkel Huinink WW, et al. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol. 2005;16:1123-1132.
22. Cao S, Durrani FA, Rustum YM. Synergistic antitumor activity of capecitabine in combination with irinotecan. Clin Colorectal Cancer. 2005;4:336-343.
23. Borner MM, Bernhard J, Dietrich D, et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol. 2005;16:282-288. Doi:10.1093/annonc/mdi047.
24. Baek JH, Kim JG, Jeon SB, et al. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br J Cancer. 2006;94:1407-1411. Doi: 10.1038/sj.bjc.6603093.
25. Chin K, Iishi H, Imamura H, et al. Irinotecan plus S-1 (IRIS) versus S-1 alone as first line treatment for advanced gastric cancer: preliminary results of a randomized phase III study (GC0301/TOP- 002). 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol. 2007;25(suppl 18S). (abstract 4525).
26. Boku N, Yamamoto S, Shirao K, et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). 2007 ASCO Annual Meeting Proceedings (Post- Meeting Edition). J Clin Oncol 2007;25(suppl 18S). (abstract 4513).
27. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-221. Doi:10.1016/S1470-2045(08).
28. Assersohn L, Brown G, Cunningham D, et al. Phase II study of irinotecan and 5-fluorouracil/leucovor in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol. 2004;15:64-69.
29. Pozzo C, Barone C, Szanto J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol. 2004;15: 1773-1781. Doi:10.1093/annonc/mdh473.
30. Cassidy J, Twelves C, Van Cutsem E, et al; Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13:566-575.
31. Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, andmitomycin C versus 5-fluorouracil alone n the treatment of advanced gastric cancer. Cancer. 1993;71:3813-3818.
32. Icli F, Celik I, Aykan F, et al. A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Cancer. 1998;83:2475-2480.
33. Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)- cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol. 2000;11:301-306.
34. Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol. 1999;17:319-323.
35. Liu JY, Qu K, Sferruzza AD, et al. Distribution of the UGT1A1. *28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals. Anti-Cancer Drugs. 2007;18:693-696. Doi: 10.1097/CAD. 0b013e32803a46fe.
36. Park SH, Bang SM, Cho EK, et al. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. Oncology. 2004;66:353-357. DOI: 10.1159/000079482.
37. Kim TW, Kang WK, Chang HM, et al. Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group rial. Acta Oncol. 2005;44:230-235. DOI 10.1080/028418605- 10029590.